BCL2 and acute myeloid leukemia: Interestingly, studies have shown that the treatment of AML cells with the selective small-molecule bromodomain inhibitor JQ1 caused the rapid downregulation of BCL2 and MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes 27, 29.